-
Reply to Jason Koehler and Abhinav Sidana’s Letter to the Editor re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.006 Eur. Urol. (IF 25.3) Pub Date : 2025-02-06 Pascal Rischmann, Bob-Valéry Occéan, Guillaume Ploussard
No Abstract
-
Re: Immunogenomic Determinants of Exceptional Response to Immune Checkpoint Inhibition in Renal Cell Carcinoma Eur. Urol. (IF 25.3) Pub Date : 2025-02-06 Hanzhong Zhang, Ying Liu, Anqi Lin, Linhui Wang, Aimin Jiang
No Abstract
-
Re: Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Eur. Urol. (IF 25.3) Pub Date : 2025-02-06 Hanzhong Zhang, Ying Liu, Peng Luo, Linhui Wang, Aimin Jiang
No Abstract
-
Characterisation of vent designs in flexible and navigable suction ureteric access sheaths BJU Int. (IF 3.7) Pub Date : 2025-02-05 Richard Menzies-Wilson, Jessica Williams, Candace Rhodes, Alycia Abbott, Thijs Ruiken, Benjamin Turney
To evaluate the different vent designs in three commercially available flexible and navigable suction (FANS) access sheaths—ClearPetra® (Well lead, Guangzhou, China), Elephant II (YIGAOMedical, Hangzhou, China) and Tuohy-Borst FANS access sheath (Seplou, Zhejiang, China)—and quantify the effects these differing designs have on the control of suction.
-
Refining partial gland ablation for localised prostate cancer: the FALCON project BJU Int. (IF 3.7) Pub Date : 2025-02-04 Lara Rodriguez-Sanchez, Xavier Cathelineau, Theo M. de Reijke, Phillip Stricker, Mark Emberton, Anna Lantz, Bernardino Miñana López, Jose Luis Dominguez-Escrig, Fernando J. Bianco, Georg Salomon, Aiman Haider, Anita Mitra, Alberto Bossi, Eva Compérat, Robert Reiter, Pilar Laguna, Gaelle Fiard, Luca Lunelli, George R. Schade, Peter Ka-Fung Chiu, Petr Macek, Veeru Kasivisvanathan, Jean J.M.C.H. Rosette
To provide a contemporary statement on focal therapy (FT) for localised prostate cancer (PCa) from an international and diverse group of physicians treating localised PCa, with the aim of overcoming the limitations of previous consensus statements, which were restricted to early adopters, and to offer direction regarding the various aspects of FT application that are currently not well defined.
-
Comparison of female and male prostate glands BJU Int. (IF 3.7) Pub Date : 2025-02-05 Britt Haller, James Brock, Eric Chung, Helen E. O’Connell
Click on the article title to read more.
-
PARP Inhibitors and Prostate Cancer: The Struggle To Separate the Grain from the Chaff Eur. Urol. (IF 25.3) Pub Date : 2025-02-03 Elena Castro, David Lorente, David Olmos
No Abstract
-
Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma Eur. Urol. (IF 25.3) Pub Date : 2025-02-03 Jens Bedke, Yasmin Abu Ghanem, Laurence Albiges, Stephanie Bonn, Riccardo Campi, Umberto Capitanio, Saeed Dabestani, Milan Hora, Tobias Klatte, Teele Kuusk, Lars Lund, Lorenzo Marconi, Carlotta Palumbo, Geraldine Pignot, Thomas Powles, Maxine Tran, Alessandro Volpe, Axel Bex
The KEYNOTE-564 trial showed that adjuvant immune checkpoint inhibitor (ICI) therapy with pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) and overall (OS) survival in localised clear-cell renal cell carcinoma (RCC) with a high risk of relapse. The TiNivo and CONTACT-03 trials have reported results for subsequent therapy after progression on ICI therapy in the metastatic
-
Re: Characterizing Psychological Resources and Resilience in Patients with Bladder Cancer: Associations with Frailty and Quality of Life Eur. Urol. (IF 25.3) Pub Date : 2025-02-03 Rodolfo Hurle, Bruno Bernardini, Roberto Contieri, Massimo Lazzeri
No Abstract
-
Recommendation on the use of protective eyewear in endourological laser procedures BJU Int. (IF 3.7) Pub Date : 2025-02-01 Tom Lister, Stan Batchelor, Mike Regan, Jason Britton, Hari Ratan, Feras Al-Jaafari, Jake Patterson
This work examines the current evidence available regarding the risks of eye injury in endourology laser environments with the aim of providing a consensus recommendation on the appropriate use of protective eyewear.
-
Global comparison of research ethical review protocols: insights from an international research collaborative BJU Int. (IF 3.7) Pub Date : 2025-01-31 Bing Jie Chow, Alexander Light, Arjun Nathan, Loic Baekelandt, Gautier Marcq, Stefanie Croghan, Fortis Gaba, Francesco Esperto, Luca Orecchia, Carlos Toribio-Vázquez, Juan Gómez Rivas, Adrian Chi-Heng Fung, Kaleab Habtemichael Gebreselassie, Eduardo Felicio, Aria Danurdoro, Nikolaos Pyrgidis, Vukovic Marko, Jan Svihra, Mohamed Javid, Andrés Salas, Tran Trung Thanh, Cameron Alexander, Nikita Bhatt,
Scientific ethical review is a cornerstone of conducting medical research. It aims to ensure human subject research is conducted in a manner that safeguards and respects participants’ rights and well-being. Research ethics committees (RECs) or institutional review boards (IRBs) are responsible for ethical evaluations before approval. This entails assessing potential risks and benefits associated with
-
Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging Perspectives Eur. Urol. (IF 25.3) Pub Date : 2025-01-31 Rui M. Bernardino, Theodorus van der Kwast, Neil E. Fleshner
Section snippets Limitations of current strategies for IDC/Crib detectionReliable detection of these aggressive subtypes remains difficult, as conventional biopsy has demonstrated limited sensitivity. Data from matched biopsy and RP studies indicate that traditional biopsy methods (with or without magnetic resonance imaging [MRI] fusion) have sensitivity as low as 42% for Crib and 44% for IDC detection
-
Impact and importance of a new men’s health strategy in England Nat. Rev. Urol. (IF 12.1) Pub Date : 2025-01-31 John Chisholm
The Government’s commitment to a Men’s Health Strategy in England, announced by Wes Streeting, the Secretary of State for Health and Social Care, on 28 November 2024, is a welcome development. The implementation of a strategy will hopefully lead to improved access to services and health outcomes for men and boys.
-
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial Eur. Urol. (IF 25.3) Pub Date : 2025-01-30 Johann S. de Bono, Meng He, Zhen Shi, Malgorzata Nowicka, Sergio Bracarda, Cora N. Sternberg, Kim N. Chi, David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Geng Chen, Nives Selak Bienz, Daniel Canter, Matthew Wongchenko, Christopher Sweeney
Background and objectiveIn the phase 3 IPATential150 trial, ipatasertib addition to abiraterone significantly reduced the risk of disease progression in men with metastatic castration-resistant prostate cancer (mCRPC) with PTEN loss on immunohistochemistry (IHC), but not in the intention-to-treat (ITT) population. Here we report the final overall survival (OS) analysis and present results for prespecified
-
Extraperitoneal single‐site robot‐assisted radical prostatectomy with extended pelvic lymph node dissection: technique and experience BJU Int. (IF 3.7) Pub Date : 2025-01-30 Yubo Wang, Mingzhao Li, Kai Yao, Zhuyinjun Zong, Yifan Chang, Yongda Liu, Chao Cai, Fadi Mousa Al Kalailah, Shancheng Ren, Guohua Zeng, Di Gu
Introduction For patients with locally advanced or high-risk localised prostate cancer who require lymph node dissection (LND), guidelines recommend an extended pelvic LND (ePLND). Such an extensive dissection ensures accurate staging information for most patients [1]. Advancements in surgical instrumentation and optimisation of surgical techniques could potentially empower surgeons to perform an ePLND
-
The 5‐year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer BJU Int. (IF 3.7) Pub Date : 2025-01-30 Vincent J. Gnanapragasam, Alexandra Keates, Artitaya Lophatananon, Vineetha Thankapannair
ObjectivesTo report 5‐year outcomes from the STRATified CANcer Surveillance (STRATCANS) programme based on progression risks using National Institute for Health and Clinical Excellence (NICE) Cambridge Prognostic Group (CPG) at diagnosis, prostate specific antigen density and magnetic resonance imaging (MRI) visibility.Patients and MethodsMen with CPG1 and CPG2 disease selecting active surveillance
-
The Cost of Bladder Cancer: What Can Be Done? Eur. Urol. (IF 25.3) Pub Date : 2025-01-29 Arnulf Stenzl
No Abstract
-
Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers Nat. Rev. Urol. (IF 12.1) Pub Date : 2025-01-29 Daniela Perotti, Maureen J. O’Sullivan, Amy L. Walz, Jonathan Davick, Reem Al-Saadi, Daniel J. Benedetti, Jack Brzezinski, Sara Ciceri, Nicholas G. Cost, Jeffrey S. Dome, Jarno Drost, Nicholas Evageliou, Rhoikos Furtwängler, Norbert Graf, Mariana Maschietto, Elizabeth A. Mullen, Andrew J. Murphy, Michael V. Ortiz, Justine N. van der Beek, Arnauld Verschuur, Jenny Wegert, Richard Williams, Filippo Spreafico
-
Epidemiology, diagnosis and treatment of anterior prostate cancer Nat. Rev. Urol. (IF 12.1) Pub Date : 2025-01-28 Sammy Gharbieh, Joshua Mullin, Ata Jaffer, Daniel Chia, Ben Challacombe
-
Growth kinetics of renal tumours during pregnancy in patients with hereditary renal cancer syndromes BJU Int. (IF 3.7) Pub Date : 2025-01-29 Nityam Rathi, Rabindra Gautam, Jason Hyman, Daniel Nethala, W. Marston Linehan, Mark W. Ball, Sandeep Gurram
Click on the article title to read more.
-
Shining a Light in the Darkness: Exploring Treatment Burden in Genitourinary Oncology Eur. Urol. (IF 25.3) Pub Date : 2025-01-27 Alicia K. Morgans, Stacy Loeb
No Abstract
-
Re: Standard or Extended Lymphadenectomy for Muscle-invasive Bladder Cancer Eur. Urol. (IF 25.3) Pub Date : 2025-01-27 Daniele Raggi, Deep Chakrabarti, Harshani Green, Robert A. Huddart
No Abstract
-
Urology on a changing planet: links between climate change and urological disease Nat. Rev. Urol. (IF 12.1) Pub Date : 2025-01-28 Alexander P. Cole, Zhiyu Qian, Natasha Gupta, Michael Leapman, Hanna Zurl, Quoc-Dien Trinh, Jodi D. Sherman, Stacy Loeb, Hari S. Iyer
-
Tumour size is associated with growth rates of >0.5 cm/year and delayed intervention in small renal masses in patients on active surveillance BJU Int. (IF 3.7) Pub Date : 2025-01-28 Maximilian Pallauf, Michael Rezaee, Roy Elias, Tina Wlajnitz, Sean A. Fletcher, Joseph Cheaib, Khalid Alkhatib, Peter Chang, Andrew A. Wagner, James M. McKiernan, Mohamad E. Allaf, Phillip M. Pierorazio, Nirmish Singla
ObjectiveTo evaluate the association between tumour size and the growth rate (GR) of small renal masses (SRMs) in patients managed by active surveillance (AS).Materials and MethodsWe queried the prospective, multi‐institutional Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry for patients on AS with an imaging interval of ≥6 months, identifying 456 patients. We tracked
-
Improving environmental sustainability in urology as a resident BJU Int. (IF 3.7) Pub Date : 2025-01-28 Bushra Abdelqader, Archie McGrath, Pinky Kotecha, John S McGrath, Joseph John
Click on the article title to read more.
-
Robotic surgery for paediatric neurogenic lower urinary tract dysfunction: a systematic review BJU Int. (IF 3.7) Pub Date : 2025-01-28 Ihtisham Ahmad, Dheidan Alshammari, Priyank Yadav, Michael Chua, Margarita Chancy, Mohd S. Ansari, Mohan S. Gundeti
ObjectiveTo evaluate in a systematic review the outcomes, benefits, and limitations of robot‐assisted surgeries for paediatric neurogenic lower urinary tract dysfunction (LUTD), as robot‐assisted techniques have emerged as a potential alternative, offering enhanced precision, dexterity, and visualisation.MethodsThis review was registered in the International Prospective Register of Systematic Reviews
-
Factors associated with urinary incontinence in nulliparous female elite athletes: an exploratory, cross-sectional study using dynamic pelvic magnetic resonance imaging and questionnaire data. J. Urol. (IF 5.9) Pub Date : 2025-01-27 Zoe S Gan,Karthik Sundaram,Ariana L Smith
PURPOSE Urinary incontinence (UI) is common in nulliparous female elite athletes, but underlying pathophysiology is inadequately understood. We examined urinary symptoms and associated pelvic floor anatomy and function in this population, hypothesizing that athletes with UI would exhibit pelvic floor findings seen in older incontinent women (e.g., pelvic floor descent and urethral hypermobility) and
-
An Artificial Intelligence Model Using Diffusion Basis Spectrum Imaging Metrics Accurately Predicts Clinically Significant Prostate Cancer. J. Urol. (IF 5.9) Pub Date : 2025-01-27 Eric H Kim,Huaping Jing,Kainen L Utt,Joel M Vetter,R Cody Weimholt,Arnold D Bullock,Alexandra P Klim,Karla A Bergeron,Jason K Frankel,Zachary L Smith,Gerald L Andriole,Sheng-Kwei Song,Joseph E Ippolito
PURPOSE Conventional prostate magnetic resonance imaging has limited accuracy for clinically significant prostate cancer (csPCa). We performed diffusion basis spectrum imaging (DBSI) prior to biopsy and applied artificial intelligence models to these DBSI metrics to predict csPCa. MATERIALS AND METHODS Between February 2020 and March 2024, 241 patients underwent prostate MRI that included conventional
-
Re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.006 Eur. Urol. (IF 25.3) Pub Date : 2025-01-24 Jason Koehler, Abhinav Sidana
No Abstract
-
Fluid intake and recurrence and progression risk of patients with non‐muscle‐invasive bladder cancer BJU Int. (IF 3.7) Pub Date : 2025-01-25 Ivy Beeren, Hilde Meijer, Antoine G. van der Heijden, Katja K.H. Aben, J. Alfred Witjes, Lambertus A.L.M. Kiemeney, Alina Vrieling
ObjectivesTo evaluate the association of pre‐ and post‐diagnosis fluid intake with non‐muscle‐invasive bladder cancer (NMIBC) recurrence and progression risk.Patients and MethodsData were used from the multicentre prospective cohort study UroLife. Participants reported pre‐diagnosis fluid intake at 6 weeks (food frequency questionnaire [FFQ]) (n = 1322) and post‐diagnosis fluid intake at 3 and 15 months
-
Comparing open and video endoscopic lymphadenectomy for penile cancer: a systematic review and meta‐analysis of prospective studies BJU Int. (IF 3.7) Pub Date : 2025-01-25 Caio Vinícius Suartz, Richard Dobrucki de Lima, Luiza Rafih Abud, Pedro Henrique Souza Brito, Ketlyn Assunção Galhardo, Thalita Bento Talizin, André Lopes Salazar, Fernando Korkes, Giuliano Guglielmetti, Stênio de Cássio Zequi, Leopoldo Alves Ribeiro‐Filho, Paul Toren, Michele Lodde
ObjectiveTo conduct the first meta‐analysis using only prospective studies to evaluate whether video endoscopic inguinal lymphadenectomy (VEIL) offers advantages in perioperative outcomes compared to open IL (OIL) in patients with penile cancer.MethodsA systematic review with meta‐analysis was conducted across multiple databases, including Cochrane Central Register of Controlled Trials (CENTRAL), the
-
Reply to Yu-Hsiang Lin, Kou-Jen Lin, and Horng-Heng Juang’s Letter to the Editor re: Massimiliano Creta, Giorgio I. Russo, Naeem Bhojani, et al. Bladder Outlet Obstruction Relief and Symptom Improvement Following Medical and Surgical Therapies for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Systematic Review. Eur Urol 2024;86:315–26 Eur. Urol. (IF 25.3) Pub Date : 2025-01-23 Massimiliano Creta, Jean-Nicolas Cornu, Ferdinando Fusco
No Abstract
-
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types Eur. Urol. (IF 25.3) Pub Date : 2025-01-23 Axel Bex, Michael Jewett, Bryan Lewis, E. Jason Abel, Laurence Albiges, Stephanie A. Berg, Gennady Bratslavsky, David Braun, James Brugarolas, Toni K. Choueiri, Antonio Finelli, Daniel George, Naomi B. Haas, A. Ari Hakimi, Hans Hammers, Michelle Hirsch, Eric Jonasch, Payal Kapur, W. Marston Linehan, Viraj Master, Grant D. Stewart
Section snippets What can we learn from other tumour types?The treatment paradigm for stage III melanoma is the role model, as well-designed, sequential clinical trials have led to the development of a personalised neoadjuvant therapy strategy that challenges the perceived standard of adjuvant immunotherapy [1]. In melanoma, pathological response status after neoadjuvant therapy is used for response-directed
-
Re: Massimiliano Creta, Giorgio I. Russo, Naeem Bhojani, et al. Bladder Outlet Obstruction Relief and Symptom Improvement Following Medical and Surgical Therapies for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Systematic Review. Eur Urol 2024;86:315–26 Eur. Urol. (IF 25.3) Pub Date : 2025-01-23 Yu-Hsiang Lin, Kou-Jen Lin, Horng-Heng Juang
No Abstract
-
-
-
-
-
Efficacy of a clinical decision support tool to promote guideline concordant evaluations in patients with high-risk microscopic hematuria: a cluster randomized quality improvement project. J. Urol. (IF 5.9) Pub Date : 2025-01-24 Richard S Matulewicz,Sarah Tsuruo,William C King,Arielle R Nagler,Zachary S Feuer,Adam Szerencsy,Danil V Makarov,Christina Wong,Isaac Dapkins,Leora I Horwitz,Saul Blecker
PURPOSE We aimed to determine whether implementation of clinical decision support (CDS) tool integrated into the electronic health record (EHR) of a multi-site academic medical center increased the proportion of patients with American Urological Association (AUA) "high risk" microscopic hematuria (MH) who receive guideline concordant evaluations. MATERIALS AND METHODS We conducted a two-arm cluster
-
Metabolic syndrome is associated with postoperative complications after holmium laser enucleation of the prostate BJU Int. (IF 3.7) Pub Date : 2025-01-24 Victoria S. Edmonds, Daniel J. Heidenberg, Connor Mayes, Carolyn Mead‐Harvey, Mitchell R. Humphreys
ObjectivesTo compare postoperative complication rates of patients with metabolic syndrome (MetS) with patients without MetS after holmium laser enucleation of the prostate (HoLEP) for management of benign prostatic hyperplasia (BPH).Patients and MethodsWe retrospectively reviewed patients aged >40 years who underwent HoLEP at our institution from 2007 to 2022. Criteria for MetS were diagnoses of at
-
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis Eur. Urol. (IF 25.3) Pub Date : 2025-01-23 Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Arifa Bibi, Muhammad Ali Khan, Manal Imran, Kaneez Zahra Rubab Khakwani, Ammad Raina, Muhammad Umair Anjum, Ewan K. Cobran, Jeremy L. Warner, Syed A. Hussain, Parminder Singh, Daniel S. Childs, Sylvan C. Baca, Jacob J. Orme, Joaquin Mateo, Neeraj Agarwal, Silke Gillessen, Mohammad Hassan Murad, Oliver Sartor, Alan H. Bryce
Background and objectiveSelection of patients harboring mutations in homologous recombination repair (HRR) genes for treatment with a PARP inhibitor (PARPi) is challenging in metastatic castration-resistant prostate cancer (mCRPC). To gain further insight, we quantitatively assessed the differential efficacy of PARPi therapy among patients with mCRPC and different HRR gene mutations. MethodsThis living
-
Re‐defining the interpretation of 24‐h urine studies for stone formers BJU Int. (IF 3.7) Pub Date : 2025-01-23 Wilson Sui, Heiko Yang, Maria C. Velasquez, Marshall L. Stoller, Thomas Chi
ObjectivesTo identify associations between 24‐h urine abnormalities and clinical risk factors for recurrent stone formers.Patients and methodsThe Registry for Stones of the Kidney and Ureter was queried for all patients who underwent 24‐h urine studies. Patients were categorised by the number of clinical risk factors for recurrent stone disease. Stone recurrence was calculated by stone events per person‐year
-
Immunotherapy‐based neoadjuvant treatment and complication rates after radical cystectomy BJU Int. (IF 3.7) Pub Date : 2025-01-23 Reuben Ben‐David, Francesco Pellegrino, Reza Mehrazin, Joel Thomas, Jack Geduldig, Sarah Lidagoster, Evan B. Garden, Kyrollis Attalla, Ahmed Eraky, Paolo Zaurito, Marco Moschini, Alberto Briganti, Francesco Montorsi, John P. Sfakianos, Peter Wiklund
ObjectiveTo assess 30‐ and 90‐day postoperative complication rates in patients who underwent robot‐assisted radical cystectomy (RARC) after receiving novel immunotherapy‐based neoadjuvant treatment.MethodsA bi‐centre analysis was conducted in patients who underwent RARC with intracorporeal urinary diversion and who received an immunotherapy‐based neoadjuvant regimen between 2017 and 2023. Complications
-
Intravesical Instillation of Chemotherapy Before Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: The REBACARE Trial Eur. Urol. (IF 25.3) Pub Date : 2025-01-22 Thomas van Doeveren, Sebastiaan Remmers, Egbert R. Boevé, Erik B. Cornel, Antoine G. van der Heijden, Kees Hendricksen, Evelyne C.C. Cauberg, Rens Jacobs, Bin K. Kroon, Annemarie M. Leliveld, Richard P. Meijer, Harm van Melick, Bob Merks, Jorg R. Oddens, Benjamin Pradere, Luc A.J. Roelofs, Diederik M. Somford, Peter de Vries, Bart Wijsman, Willemijn A.K.M. Windt, Joost L. Boormans
Background and objectiveIntravesical instillation of chemotherapy (IIC) after radical surgery for upper urinary tract urothelial carcinoma (UTUC) reduces the risk of intravesical recurrence (IVR). However, compliance is low because of possible extravesical leakage after bladder cuff excision. The aim of this study was to evaluate the efficacy of preoperative IIC in reducing the risk of IVR. MethodsIn
-
Bladder Cancer Recurrence Following Management of Upper Tract Urothelial Carcinoma: Balancing Prevention and Iatrogenicity Eur. Urol. (IF 25.3) Pub Date : 2025-01-21 Alexandra Masson-Lecomte
No Abstract
-
Prevalence, Diagnosis, and Management of Stress Urinary Incontinence in Women: A Collaborative Review Eur. Urol. (IF 25.3) Pub Date : 2025-01-22 Lisa Moris, John Heesakkers, Victor Nitti, Helen E. O’Connell, Benoit Peyronnet, Maurizio Serati, Muhammad Imran Omar, Chris Harding
Stress urinary incontinence (SUI), defined as any involuntary leakage of urine associated with physical activity, remains underdiagnosed and undertreated. This review aims to provide an updated overview of the prevalence, diagnosis, and treatment of SUI in women, drawing upon recent evidence-based literature and clinical guidelines.
-
An AI-Digital Pathology Algorithm Predicts Survival after Radical Prostatectomy from the PLCO Trial. J. Urol. (IF 5.9) Pub Date : 2025-01-22 Eric V Li,Yi Ren,Jacqueline Griffin,Colin Han,Rikiya Yamashita,Akinori Mitani,Ruoji Zhou,Huei-Chung Huang,Ximing Yang,Felix Y Feng,Andre Esteva,Hiten D Patel,Edward M Schaeffer,Lee A D Cooper,Ashley E Ross
PURPOSE Clinical variables alone have limited ability to determine which patients will have recurrence after radical prostatectomy (RP). We evaluated the ability of locked multimodal artificial intelligence (MMAI) algorithms trained on prostate biopsy specimens to predict prostate cancer specific mortality (PCSM) and overall survival (OS) among patients undergoing radical prostatectomy with digitized
-
Randomised controlled feasibility trial of retroperitoneal vs transperitoneal robot‐assisted partial nephrectomy: the ROPARN study BJU Int. (IF 3.7) Pub Date : 2025-01-22 Sebastian Kälble, Simon U. Engelmann, Hannah Schrutz, Florian Zeman, Emily Rinderknecht, Maximilian Haas, Christoph Pickl, Christopher Goßler, Yushan Yang, Stefan Denzinger, Maximilian Burger, Johannes Bründl, Roman Mayr
ObjectivesTo assess the feasibility of trial recruitment and confirm that retroperitoneal robotic partial nephrectomy (RRPN) has the same oncological efficacy as transperitoneal robotic partial nephrectomy (TRPN), with time advantages and less peri‐operative morbidity, in a randomised controlled trial (RCT).Patients and MethodsThe study was designed as a single‐centre, open‐label, feasibility RCT.
-
Association of prostate‐specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result BJU Int. (IF 3.7) Pub Date : 2025-01-22 Juho Pylväläinen, Kirsi Talala, Jani Raitanen, Antti Rannikko, Anssi Auvinen
ObjectiveTo assess the association between prostate‐specific antigen (PSA) density (PSAD) and prostate cancer mortality after a benign result on systematic transrectal ultrasonography (TRUS)‐guided prostate biopsy.Patients and MethodsThis retrospective study used data from the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) collected between 1996 and 2020. We identified men aged
-
Re: Robert Huddart, Shaista Hafeez, Clare Griffin, et al. Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomized Controlled Trial. Eur Urol 2025;87:60–70 Eur. Urol. (IF 25.3) Pub Date : 2025-01-21 Laura E. Davis, Adam Calaway, Jonathan Shoag
No Abstract
-
The Co-IMPACT Consortium: Integrating Prostate-specific Membrane Antigen Positron Emission Tomography and Radiotherapy in Prostate Cancer Care Eur. Urol. (IF 25.3) Pub Date : 2025-01-20 Vedang Murthy, Giulia Marvaso, Barbara A. Jereczek-Fossa, Stephanie A. Thoma, Marco Vogel, Nina-Sophie Schmidt-Hegemann, Mohamed Shelan, Shankar Siva, Tobias Hoelscher, Amar U. Kishan, Jan C. Peeken, Silke Gillessen, Matthias Guckenberger, Ken Herrmann, Wolfgang P. Fendler, Thomas Zilli, Simon K.B. Spohn, Constantinos Zamboglou
No Abstract
-
Multi-Institutional Analysis of Surgery for Lichen Sclerosus-Induced Penile Urethral Stricture: Establishing Single-Stage Urethroplasty as a Primary Treatment Option. J. Urol. (IF 5.9) Pub Date : 2025-02-05 Ross Hengel,Alex Vanni,Brad Erickson,Sean Elliott,Ben Breyer,Jill C Buckley,Josh Broghammer,Bryan Voelzke,Jeremy Myers,Keith Rourke
PURPOSE Ideal treatment of lichen sclerosus (LS)-induced penile urethral strictures (PUS) remains elusive. The objective of this study was to compare multi-institutional outcomes of single-stage urethroplasty (SSU) with oral mucosal graft, staged urethroplasty, and perineal urethrostomy (PU) for treatment of LS-induced PUS. MATERIALS AND METHODS Multi-institutional analysis was performed at 9 centers
-
IMPACT OF 3D-PRINTED MODELS FOR SURGICAL PLANNING IN RENAL CELL CARCINOMA WITH VENOUS TUMOR THROMBUS. A RANDOMISED MULTICENTER CLINICAL TRIAL. J. Urol. (IF 5.9) Pub Date : 2025-01-21 I Rivero-Belenchón,C B Congregado Ruíz,G Gómez Ciriza,V Gómez Dos Santos,F J Burgos Revilla,R A Medina López
PURPOSE To determine whether surgical planning based on 3D models allows for better surgical outcomes than conventional surgical planning in terms of 1) complications, 2) surgical time, and 3) hospital stay. MATERIALS AND METHODS This multicenter clinical trial (NCT03738488) included 66 patients diagnosed with renal cell carcinoma and venous thrombus extension who underwent nephrectomy with thrombectomy
-
Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non-Digital Rectal Examination Urine. J. Urol. (IF 5.9) Pub Date : 2025-01-21 Jeffrey J Tosoian,Yuping Zhang,Jacob I Meyers,Spencer Heaton,Javed Siddiqui,Lanbo Xiao,Keavash D Assani,Daniel A Barocas,Ashley E Ross,Zoey Chopra,Grace C Herron,Jacob A Edelson,Nathan J Graham,Udit Singhal,Simpa S Salami,Todd M Morgan,Ganesh S Palapattu,John T Wei,Arul M Chinnaiyan
PURPOSE The 18-gene MyProstateScore 2.0 (MPS2) test was previously validated for detection of grade group ≥ 2 (GG ≥ 2) prostate cancer using post-digital rectal examination (DRE) urine. To improve ease of testing, we validated MPS2 using first-catch, non-DRE urine. MATERIALS AND METHODS Patients provided first-catch urine before biopsy. MPS2 values were calculated using previously validated models
-
Rethinking routine histological analysis of transurethral resection of the prostate tissue samples: cost, relevance, and patient impact BJU Int. (IF 3.7) Pub Date : 2025-01-21 Aikaterini Eleftheriadou, James Aljoe, Matthew Deacon, Vishwas Iyer, Nimalan Arumainayagam
Click on the article title to read more.
-
February's reviewers of the month BJU Int. (IF 3.7) Pub Date : 2025-01-21
Click on the article title to read more.
-
-
Outcomes of prostate cancer treatments BJU Int. (IF 3.7) Pub Date : 2025-01-21
Click on the article title to read more.
-
The COVID‐19 pandemic and Urology – reflecting on successful initiatives and lessons in Australia BJU Int. (IF 3.7) Pub Date : 2025-01-20 Jennifer Xu, Matthew Alberto, Dixon Woon, Damien Bolton, Joseph Ischia
ObjectivesTo summarise the impact of the coronavirus disease 2019 (COVID‐19) pandemic on urological practice globally with a focus on Australian initiatives, as the pandemic resulted in radical changes in healthcare infrastructure and policies.MethodsWe conducted a literature review of the Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE) and Web of
-
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis Eur. Urol. (IF 25.3) Pub Date : 2025-01-17 Silke Gillessen, Bertrand Tombal, Fabio Turco, Ananya Choudhury, Alejo Rodriguez-Vida, Enrique Gallardo, Pedro Isaacsson Velho, Franco Nolè, Felipe Cruz, Yohann Loriot, Ray McDermott, Thierry Roumeguere, Gedske Daugaard, Rosley Yamamura, Emmanuelle Bompas, Pablo Maroto, Manuel Herrero Polo, Karine Martins da Trindade, Daniel D’Almeida Preto, Iwona Skoneczna, Fred Saad
Bone health is central to the management of patients with metastatic castration-resistant prostate cancer (mCRPC). International guidelines recommend giving a bone-protecting agent (BPA) to patients with mCRPC and bone metastases. However, the data supporting these recommendations were generated before androgen receptor pathway inhibitors (ARPIs) were available. Here we publish for the first time fracture